Compare McDonald's Corp (MCD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Tango Therapeutics Inc. — how do they compare? McDonald's Corp trades at $243.7 (market cap $168.64B), while Tango Therapeutics Inc. trades at $22.76 (market cap $3.74B). The key difference: McDonald's Corp is far larger — about 45.1× Tango Therapeutics Inc.'s market cap, and McDonald's Corp pays a 3.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 165 Days and Tango Therapeutics Inc. for 0 Days on average.
| MCD | TNGX | |
|---|---|---|
Market Cap | $168.64B | $3.74B |
Volume | 5,186,233 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $32.90 |
52-Week Low | $230.88 | $7.50 |
Typical Hold Time | 165 Days | 0 Days |
Enterprise Value | $222.41B | $2.76B |
Dividend Yield | 3.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $235.81, up 0.07% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth is steady, reaching $26.89B in 2025, while net income margin remains robust at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and menu innovation to drive growth.
The outlook is supported by analyst optimism with a consensus price target of $284.70, implying significant upside. However, risks include inflationary pressures on franchisee margins and high long-term debt of $38.42B. The stock presents a value opportunity with a P/E of 19.16, but investors should weigh execution risks against growth initiatives.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
